Darolutamide May Be an Effective Alternative Treatment Option for mHSPC

The ARANOTE study, presented by Fred Saad at ESMO 2024, evaluated the use of darolutamide plus ADT in men with metastatic hormone-sensitive prostate cancer (mHSPC). It showed that darolutamide had a favorable safety profile, with fewer discontinuations and less fatigue than the placebo. Darolutamide may then offer an effective alternative treatment option for mHSPC without the need for docetaxel.